cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

RecruitingOBSERVATIONAL
Enrollment

7,000

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2026

Conditions
Brain CancerBreast CancerBladder CancerCervical CancerColorectal CancerEndometrial CancerEsophageal CancerStomach CancerHead and Neck CancerHepatobiliary CancerLeukemiaLung CancerLymphomaMultiple MyelomaOvarian CancerPancreatic CancerProstate CancerRenal CancerSarcomaThyroid Cancer
Trial Locations (15)

29502

RECRUITING

McLeod Health, Florence

33176

RECRUITING

Miami Cancer Institute, Miami

37203

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

38120

RECRUITING

Baptist (BHMCC), Memphis

40503

RECRUITING

Baptist Lexington, Lexington

40701

RECRUITING

Baptist Corbin, Corbin

42003

WITHDRAWN

Baptist Paducah, Paducah

42701

RECRUITING

Baptist Hardin, Elizabethtown

44195

RECRUITING

Cleveland Clinic, Cleveland

47150

RECRUITING

Baptist Floyd, New Albany

55902

RECRUITING

Mayo Clinic, Rochester

78704

RECRUITING

Elligo Health Research, Inc., Austin

91010

RECRUITING

City of Hope, Duarte

97201

RECRUITING

Oregon Health Sciences University, Portland

306501

RECRUITING

North Georgia Health System, Gainesville

All Listed Sponsors
lead

Adela, Inc

INDUSTRY